Citigroup Cuts Teladoc Health (NYSE:TDOC) Price Target to $7.50

Teladoc Health (NYSE:TDOC) had its price target lowered by research analysts at Citigroup from $11.00 to $7.50 in a note issued to investors on Monday,Benzinga reports. The brokerage currently has a “neutral” rating on the health services provider’s stock. Citigroup’s target price would suggest a potential upside of 13.38% from the company’s current price.

A number of other equities research analysts have also commented on TDOC. Bank of America increased their price target on Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Weiss Ratings raised shares of Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Finally, Canaccord Genuity Group lowered their price target on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating for the company in a report on Thursday. Five research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $7.54.

Teladoc Health Stock Performance

Shares of NYSE TDOC traded down $0.10 during midday trading on Monday, reaching $6.62. 3,703,648 shares of the company traded hands, compared to its average volume of 5,551,685. Teladoc Health has a 12 month low of $4.40 and a 12 month high of $9.89. The stock’s 50-day simple moving average is $8.21 and its 200-day simple moving average is $6.54. The firm has a market cap of $1.19 billion, a PE ratio of -6.69 and a beta of 2.10.

Teladoc Health (NYSE:TDOC) last posted its earnings results on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.04. The business had revenue of $606.93 million for the quarter, compared to analyst estimates of $615.44 million. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. The firm’s quarterly revenue was down 4.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.19) EPS. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. On average, equities research analysts expect that Teladoc Health will post -0.88 EPS for the current year.

Insider Buying and Selling at Teladoc Health

In other news, insider Fernando M. Rodrigues sold 5,677 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $43,315.51. Following the transaction, the insider owned 9,572 shares of the company’s stock, valued at $73,034.36. This represents a 37.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Charles Divita III sold 19,132 shares of the stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total value of $145,977.16. Following the completion of the transaction, the chief executive officer directly owned 389,894 shares in the company, valued at approximately $2,974,891.22. This trade represents a 4.68% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 39,195 shares of company stock valued at $299,058 in the last three months. Insiders own 0.70% of the company’s stock.

Hedge Funds Weigh In On Teladoc Health

Hedge funds have recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC boosted its holdings in Teladoc Health by 694.5% during the first quarter. EverSource Wealth Advisors LLC now owns 5,657 shares of the health services provider’s stock worth $31,000 after buying an additional 4,945 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Teladoc Health by 177.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock valued at $31,000 after acquiring an additional 2,810 shares during the last quarter. IFP Advisors Inc raised its position in shares of Teladoc Health by 412.1% in the 3rd quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock valued at $31,000 after acquiring an additional 3,210 shares during the period. International Assets Investment Management LLC bought a new position in Teladoc Health during the 4th quarter worth approximately $45,000. Finally, Van ECK Associates Corp boosted its stake in Teladoc Health by 101.4% during the 4th quarter. Van ECK Associates Corp now owns 9,150 shares of the health services provider’s stock worth $64,000 after acquiring an additional 4,607 shares during the last quarter. Institutional investors and hedge funds own 76.82% of the company’s stock.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.